BR0308202A - Tiazóis e oxazóis substituìdos que modulam a atividade de ppar - Google Patents

Tiazóis e oxazóis substituìdos que modulam a atividade de ppar

Info

Publication number
BR0308202A
BR0308202A BR0308202-4A BR0308202A BR0308202A BR 0308202 A BR0308202 A BR 0308202A BR 0308202 A BR0308202 A BR 0308202A BR 0308202 A BR0308202 A BR 0308202A
Authority
BR
Brazil
Prior art keywords
ppar activity
compounds
oxazoles
relates
substituted thiazoles
Prior art date
Application number
BR0308202-4A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0308202A publication Critical patent/BR0308202A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"TIAZóIS E OXAZóIS SUBSTITUìDOS QUE MODULAM A ATIVIDADE DE PPAR". A presente invenção refere-se a compostos de estruturas (1) e (2) que alteram a atividade de PPAR. A invenção refere-se também a sais farmaceuticamente aceitáveis dos compostos, composições farmaceuticamente aceitáveis compreendendo os compostos ou seus sais, e métodos de uso deles como agentes terapêuticos para tratamento ou prevenção de hiperlipidemia e hipercolesterolemia em um mamífero. A presente invenção referese também a um método de fabricação dos compostos descritos.
BR0308202-4A 2002-03-07 2003-03-03 Tiazóis e oxazóis substituìdos que modulam a atividade de ppar BR0308202A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36241102P 2002-03-07 2002-03-07
PCT/IB2003/000882 WO2003074051A1 (en) 2002-03-07 2003-03-03 Substituted thiazoles and oxazoles that modulate ppar activity

Publications (1)

Publication Number Publication Date
BR0308202A true BR0308202A (pt) 2004-12-21

Family

ID=27789158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308202-4A BR0308202A (pt) 2002-03-07 2003-03-03 Tiazóis e oxazóis substituìdos que modulam a atividade de ppar

Country Status (15)

Country Link
US (3) US6867224B2 (pt)
EP (1) EP1480641A1 (pt)
JP (1) JP2005527509A (pt)
AR (1) AR038882A1 (pt)
AU (1) AU2003207914A1 (pt)
BR (1) BR0308202A (pt)
CA (1) CA2478164A1 (pt)
GT (1) GT200300054A (pt)
MX (1) MXPA04008627A (pt)
NI (1) NI200300039A (pt)
PA (1) PA8568601A1 (pt)
PE (1) PE20040190A1 (pt)
TW (1) TW200405812A (pt)
UY (1) UY27696A1 (pt)
WO (1) WO2003074051A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276074B2 (ja) * 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004092131A1 (en) * 2003-01-06 2004-10-28 Eli Lilly And Company Indole derivatives as ppar modulators
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005005423A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
JP2007509996A (ja) * 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのヘテロアリール誘導体
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
KR100802864B1 (ko) * 2004-03-09 2008-02-12 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 피라졸릴 인돌릴 유도체
WO2005085235A1 (en) 2004-03-09 2005-09-15 F. Hoffmann-La Roche Ag Pyrazolyl indolyl derivatives as ppar activators
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
CA2567437A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
WO2006054166A1 (en) * 2004-11-18 2006-05-26 Pfizer Products Inc. Drugs and prodrugs useful for the treatment of energy balance in ruminants
CA2599348C (en) 2005-02-25 2013-07-23 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US8202686B2 (en) * 2007-03-22 2012-06-19 Advanced Liquid Logic, Inc. Enzyme assays for a droplet actuator
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
EP2516669B1 (en) 2009-12-21 2016-10-12 Advanced Liquid Logic, Inc. Enzyme assays on a droplet actuator
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
RU2560147C2 (ru) 2010-06-21 2015-08-20 Оно Фармасьютикал Ко., Лтд. Новые кристаллические формы 4, 4'- [4-фтор-7({4-[4-(3-фтор-2-метилфенил)бутокси]фенил}этинил)-2-метил-1н-индол-1, 3-диил]дибутановой кислоты, 4, 4'-[2-метил-7-({4-[4-(пентафторфенил)бутокси] фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты и 4, 4'-[4-фтор-2-метил-7-({4-[4-(2, 3, 4, 6-тетрафторфенил) бутокси]фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты
US9513253B2 (en) 2011-07-11 2016-12-06 Advanced Liquid Logic, Inc. Droplet actuators and techniques for droplet-based enzymatic assays
CA2864990C (en) * 2012-02-24 2021-03-02 Nobuyuki Takakura Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat)
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
US6756403B2 (en) 2000-06-02 2004-06-29 Eli Lilly And Company Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
US6903227B2 (en) 2000-06-02 2005-06-07 Millennium Pharmaceuticals, Inc. Synthesis of 2-acyl substituted chromanes and intermediates thereof
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
SK1872003A3 (en) 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
EP1398313A4 (en) 2001-05-29 2005-11-16 Kyoto Pharma Ind NEW HETEROCYCLIC DERIVATIVES AND THEIR MEDICAL USE
US7282501B2 (en) 2001-06-07 2007-10-16 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (PPAR)
US6924295B2 (en) 2001-06-18 2005-08-02 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
AU2003207914A1 (en) 2003-09-16
AR038882A1 (es) 2005-02-02
WO2003074051A1 (en) 2003-09-12
JP2005527509A (ja) 2005-09-15
US7109222B2 (en) 2006-09-19
US20050113422A1 (en) 2005-05-26
US20050107442A1 (en) 2005-05-19
UY27696A1 (es) 2003-10-31
PA8568601A1 (es) 2003-11-12
GT200300054A (es) 2003-10-10
TW200405812A (en) 2004-04-16
MXPA04008627A (es) 2004-12-06
EP1480641A1 (en) 2004-12-01
CA2478164A1 (en) 2003-09-12
US6867224B2 (en) 2005-03-15
NI200300039A (es) 2005-09-21
US20030207915A1 (en) 2003-11-06
PE20040190A1 (es) 2004-03-20

Similar Documents

Publication Publication Date Title
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
BR0308277A (pt) Derivados tiazol e oxazol que modulam a atividade de ppar
BRPI0409486A (pt) compostos que modulam atividade de ppar e métodos para a sua preparação
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
DE59802356D1 (de) Lagerstabile ophthalmische zusammensetzungen, umfassend diclofenac und ofloxacin
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0015436A (pt) Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
DK1317262T3 (da) Topisk påført koncentreret sammensætning til hovbehandling
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
IS6105A (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4
BR0314843A (pt) Novo composto
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
DK1197223T3 (da) Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.